Effects of Imatinib Mesylate on Renin–Angiotensin System (RAS) Activity during the Clinical Course of Chronic Myeloid Leukaemia
| Autor: | Muge Sayitoglu, Mustafa Nuri Yenerel, Cem Ar, Osman Ilhan, M. Yilmaz, S Dagdas, Yucel Erbilgin, Leylagül Kaynar, A Tukun, Ugur Ozbek, Ozden Hatirnaz, Meltem Olga Akay, O.I. Özcebe, Cafer Adiguzel, G Ozet, Ebru Koca, B Durgun, Teoman Soysal, Yildiz Aydin, Mahmut Bayik, Ali Ünal, Salih Aksu, E Ovali, Ibrahim C. Haznedaroglu, Ibrahim Akalin, Zafer Gulbas |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Angiotensinogen Gene Expression Peptidyl-Dipeptidase A Biochemistry Piperazines Renin-Angiotensin System Young Adult Bone Marrow Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols Renin Renin–angiotensin system medicine Humans Protein Kinase Inhibitors Aged Aged 80 and over business.industry Biochemistry (medical) Imatinib Cell Biology General Medicine Middle Aged medicine.disease Leukemia Haematopoiesis Pyrimidines Endocrinology medicine.anatomical_structure Imatinib mesylate Benzamides Imatinib Mesylate Cancer research Neoplastic cell Drug Therapy Combination Female Bone marrow business Tyrosine kinase medicine.drug |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 1473-2300 0300-0605 |
| DOI: | 10.1177/147323000903700406 |
| Popis: | The renin–angiotensin system (RAS) is involved in cell growth, proliferation and differentiation in bone marrow in an autocrine–paracrine manner, and it modulates normal and neoplastic haematopoietic cell proliferation. This study aimed to assess expressions of the RAS components, renin, angiotensinogen and angiotensin-converting enzyme (ACE), during imatinib mesylate treatment of patients with chronic myeloid leukaemia (CML). Expressions of RAS components were studied in patients with CML at the time of diagnosis ( n = 83) and at 3, 6 and 12 months after diagnosis ( n = 35) by quantitative real-time polymerase chain reaction. De novo CML patients had increased ACE, angiotensinogen and renin mRNA levels and these expression levels decreased following administration of imatinib. The RAS activities were significantly different among Sokal risk groups of CML, highlighting the altered biological activity of RAS in neoplastic disorders. The results of this study confirm that haematopoietic RAS affects neoplastic cell production, which may be altered via administration of tyrosine kinase inhibitors such as imatinib mesylate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|